A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Inclusion Criteria:

• Male or female, 18 to 55 years of age (inclusive) at the time of signing theinformed consent.

• Body mass index (BMI) ≥ 18.5 and 32 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive)

• Subjects must be judged to be in good health based upon the results of a medicalhistory, physical examination, vital signs, 12-lead electrocardiogram and laboratoryprofile

• Voluntary consent to participate in the study.

Exclusion Criteria:

• History or presence of significant cardiovascular, pulmonary, hepatic, renal,hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,or psychiatric disease.

• A subject with active drug or alcohol abuse within 2 years prior to the initialstudy drug administration

• Females who are pregnant or lactating

• Documented hypersensitivity reaction or anaphylaxis to any medication. History ofany severe hypersensitivity, anaphylaxis, or allergic reaction to cefiderocol or anyother beta-lactam antibacterial drugs, or any other excipients used in theformulation (eg, cephalosporins, penicillins, carbapenems, or monobactams)